Shandong Buchang Pharmaceuticals Co., Ltd. (SHA:603858)
China · Delayed Price · Currency is CNY 14.64
-0.15 (-1.01%)
Jun 9, 2026, 3:00 PM CST
SHA:603858 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 11,640 | 11,846 | 10,974 | 13,229 | 14,942 | 15,755 |
Other Revenue | 29.04 | 29.04 | 32.06 | 16.62 | 9.62 | 7.36 |
| 11,669 | 11,875 | 11,006 | 13,245 | 14,951 | 15,763 | |
Revenue Growth (YoY) | 4.65% | 7.90% | -16.91% | -11.41% | -5.15% | -1.52% |
Cost of Revenue | 4,561 | 4,680 | 4,552 | 4,321 | 4,268 | 4,134 |
Gross Profit | 7,108 | 7,195 | 6,454 | 8,924 | 10,683 | 11,629 |
Selling, General & Admin | 5,515 | 5,671 | 5,333 | 7,365 | 8,387 | 9,237 |
Research & Development | 237.79 | 240.1 | 345.41 | 335.08 | 284.12 | 408.6 |
Other Operating Expenses | 134.09 | 123.06 | 120.01 | 181.03 | 232.07 | 226.9 |
Operating Expenses | 5,907 | 6,021 | 5,773 | 7,889 | 8,907 | 9,888 |
Operating Income | 1,201 | 1,174 | 680.71 | 1,035 | 1,776 | 1,741 |
Interest Expense | -118.68 | -118.7 | -129.59 | -109.93 | -135.1 | -167.29 |
Interest & Investment Income | 4.03 | 4.84 | 20.55 | 40.12 | 22.61 | 41.34 |
Currency Exchange Gain (Loss) | 2.02 | 2.02 | 0.19 | 0.08 | 0.45 | -0.12 |
Other Non Operating Income (Expenses) | 6.49 | -0.56 | -3.88 | -47.33 | -11.43 | -6.73 |
EBT Excluding Unusual Items | 1,095 | 1,062 | 567.97 | 918.42 | 1,652 | 1,608 |
Impairment of Goodwill | -219.3 | -219.3 | -853.03 | -598.03 | -2,943 | -10.15 |
Gain (Loss) on Sale of Investments | -305.1 | -283.33 | -0.15 | -2.36 | -56.79 | -60 |
Gain (Loss) on Sale of Assets | -0.52 | -0.59 | -1.62 | -2.47 | -0.66 | -0.59 |
Asset Writedown | -29.93 | -28.28 | -0.25 | -0.3 | - | - |
Other Unusual Items | 0.42 | 3.6 | -78.21 | 79.3 | 88.51 | 176.49 |
Pretax Income | 540.41 | 533.96 | -365.29 | 394.56 | -1,259 | 1,714 |
Income Tax Expense | 334.9 | 341.66 | 337.1 | 242.69 | 331.59 | 478.29 |
Earnings From Continuing Operations | 205.51 | 192.3 | -702.39 | 151.87 | -1,591 | 1,235 |
Minority Interest in Earnings | 168.43 | 168.49 | 148.6 | 167.11 | 61.24 | 53.84 |
Net Income | 373.94 | 360.78 | -553.8 | 318.97 | -1,530 | 1,289 |
Net Income to Common | 373.94 | 360.78 | -553.8 | 318.97 | -1,530 | 1,289 |
Net Income Growth | - | - | - | - | - | -30.72% |
Shares Outstanding (Basic) | 1,054 | 1,056 | 1,084 | 1,106 | 1,106 | 1,106 |
Shares Outstanding (Diluted) | 1,054 | 1,056 | 1,084 | 1,106 | 1,106 | 1,106 |
Shares Change (YoY) | -1.78% | -2.55% | -2.01% | -0.00% | -0.01% | 0.01% |
EPS (Basic) | 0.35 | 0.34 | -0.51 | 0.29 | -1.38 | 1.17 |
EPS (Diluted) | 0.35 | 0.34 | -0.51 | 0.29 | -1.38 | 1.17 |
EPS Growth | - | - | - | - | - | -30.72% |
Free Cash Flow | 341.77 | 1,034 | 742.96 | -725.52 | 2,212 | 886.98 |
Free Cash Flow Per Share | 0.32 | 0.98 | 0.69 | -0.66 | 2.00 | 0.80 |
Dividend Per Share | 0.570 | 0.570 | - | 0.126 | 0.960 | 0.360 |
Dividend Growth | - | - | - | -86.88% | 166.67% | -31.56% |
Gross Margin | 60.91% | 60.59% | 58.64% | 67.38% | 71.45% | 73.77% |
Operating Margin | 10.29% | 9.89% | 6.19% | 7.82% | 11.88% | 11.04% |
Profit Margin | 3.20% | 3.04% | -5.03% | 2.41% | -10.23% | 8.18% |
Free Cash Flow Margin | 2.93% | 8.71% | 6.75% | -5.48% | 14.80% | 5.63% |
EBITDA | 1,604 | 1,617 | 1,283 | 1,612 | 2,256 | 2,233 |
EBITDA Margin | 13.75% | 13.62% | 11.66% | 12.17% | 15.09% | 14.17% |
D&A For EBITDA | 403.1 | 443.03 | 602.77 | 576.49 | 479.96 | 492.39 |
EBIT | 1,201 | 1,174 | 680.71 | 1,035 | 1,776 | 1,741 |
EBIT Margin | 10.29% | 9.89% | 6.19% | 7.82% | 11.88% | 11.04% |
Effective Tax Rate | 61.97% | 63.99% | - | 61.51% | - | 27.91% |
Revenue as Reported | 11,669 | 11,875 | 11,006 | 13,245 | 14,951 | 15,763 |
Advertising Expenses | - | 12.18 | 27.08 | 41.38 | - | - |